Encouraging results for anti-tau antibody presented at CTAD 2024
UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease.
The results were presented during a late-breaking symposium at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Madrid, Spain.
In the overall study population, no beneficial effect of low- or high-dose bepranemab compared with placebo was observed on the primary endpoint, Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score at Week 80 (CDR-SB is a measure of cognition and function).
However, at Week 80, in key secondary endpoints, treatment with bepranemab (45mg/kg and 90mg/kg) slowed the rate of tau accumulation versus placebo in key brain regions by 33-58%, and slowed cognitive decline by 21-25% versus placebo.
In two predefined subgroups, low tau burden at Baseline and APOε4 non-carriers, treatment benefits were observed across multiple outcome measures.
In a post-hoc subgroup analysis comprising participants with low tau at baseline or those who are APOε4 non-carriers, high-dose bepranemab (90mg/kg) slowed the rate of tau accumulation in key brain regions by 63-67% and slowed clinical disease progression by 29% at Week 80.
Bepranemab is a monoclonal antibody (mAb) that specifically targets a mid-region epitope of human tau.
“We are deeply encouraged by the proof-of-concept data for bepranemab, which highlight its potential to impact early Alzheimer’s disease progression. This strengthens our belief in the value of targeting the mid-region of tau as an important strategy in altering the trajectory of the disease,” said Alistair Henry, Chief Scientific Officer at UCB.
